USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: PolyMedix, Inc.
Address: 170 N. Radnor-Chester Road
RADNOR, PA
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (484) 598-2334

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,055,758.00 8
SBIR Phase II $7,764,337.00 4
STTR Phase I $169,891.00 2
STTR Phase II $1,499,720.00 2

Award List:

Animal Testing of Biomimetic Antimicrobial Oligomers

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $238,800.00
Abstract:
DESCRIPTION (provided by applicant): Computational methodologies have been developed for the design of biomimetic polymers that 1) mimic key biological properties of proteins and 2) are more stable and inexpensive to produce than natural proteins. The first application of this technology has been… More

Biomimetic antimicrobials for biowarfare pathogens

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $167,650.00
Abstract:
DESCRIPTION (provided by applicant): The CDC has identified a number of bacteria as potential biowarfare agents. A current strategy to control infections following a bioterroristic attack is through the use of antimicrobial agents for both prophylactic and therapeutic purposes. The most significant… More

Biomimetic Polymers for an Antiseptic Handwash

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $113,238.00
Abstract:
DESCRIPTION (provided by applicant): Nosocomial (hospital-acquired) infections have become a major healthcare issue, affecting at least two million patients annually in the US. Is estimated that such infections cause or contribute to approximately 88,000 deaths per year and over 4.5 billion dollars… More

Therapeutic Development of Antimicrobial Biomimetics

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $2,865,265.00
Abstract:
DESCRIPTION (provided by applicant): The incidence of healthcare-acquired infections has increased significantly in recent years and has become an important cause of morbidity and mortality in hospitals in the US and worldwide. The continuing emergence of drug resistance in clinically-important… More

Development of biomimetic oligomers as anti-coagulant antagonists

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Unfractionated heparin (UFH) and the low molecular weight heparins (LMWHs) are widely used anti-coagulants employed in a number of clinical and surgical applications. Common adverse events associated with the use of hep arin as anti-coagulant therapy are bleeding… More

A Novel Antimicrobial Peptide Mimetic For Oral Candidiasis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $125,600.00
Abstract:
DESCRIPTION (provided by applicant): Oral infections of Candida albicans represent an increasing problem in human health. In immunocompromised individuals, especially those suffering from AIDS, Candidiasis can result in both localized, yet painful lesions in the oral cavity and life-threatening… More

Novel Antibacterial Agents

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency / Branch: DOD / NAVY
Research Institution: University of Massachusetts, Amhers
Principal Investigator: Richard W. Scott, VP Research, PolyMedix
Award Amount: $69,891.00
RI Contact: Carol P. Sprague
Abstract:
The need for novel antibiotics is well understood by anyone familiar to the field. We have discovered a novel class of antibiotics that are structurally unique from all previously known antibiotics and appear to operate via a distinctive mode of action. As a result, these new agents appear to… More

Biomimetics for treating biofilm-embedded infections

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency / Branch: DOD / ARMY
Research Institution: University of Massachusetts, Amherst
Principal Investigator: Richard W. Scott, VP Research, PolyMedix
Award Amount: $100,000.00
RI Contact: Carol Sprague
Abstract:
Multi-drug resistant (MDR) biofilms are perhaps the most difficult bacterial infections to fight. They require novel antibiotics that operate through new mechanisms which overcome the biofilm environment. We have discovered a class of antibiotics that are novel and have new targets which appear to… More

Development of biomimetic oligomers as anticoagulant antagonists

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $923,075.00
Abstract:
DESCRIPTION (provided by applicant): LMWHs are being used with greater frequency to treat deep vein thrombosis, unstable angina, and acute pulmonary embolism, as well as thromboprophylaxis agents in a wide range of clinical situations including orthopedic surgery, high risk pregnancy, and cancer… More

A Novel Antimicrobial Mimetic for Oral Candidiasis

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $975,997.00
Abstract:
DESCRIPTION (provided by applicant): Oral infections of Candida albicans represent an increasing problem in human health. In immunocompromised individuals, especially those suffering from AIDS, candiasis can result in both localized, yet painful lesions in the oral cavity as well as… More

Biomimetics for treating biofilm-embedded infections

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency / Branch: DOD / ARMY
Research Institution: University of Massachusetts Amherst
Principal Investigator: Richard W. Scott, VP Research
Award Amount: $749,860.00
RI Contact: Carol Sprague
Abstract:
Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop new antibiotics that operate through novel mechanisms which overcome the biofilm environment.… More

Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott
Award Amount: $999,094.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is a global disease causing gt 500 million clinical cases and gt 1 million deaths each year. Moreover, drug resistant Plasmodium falciparum has become a major problem. Therefore, it is crucial to discover new c lasses of drugs for anti-malarial drug… More

SBIR Phase I:Development of Novel Antimicrobial Sutures

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: NSF
Principal Investigator: richard scott, PhD
Award Amount: $150,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project is aimed at the development of antimicrobial sutures containing an active agent that displays broad activity against pathogens associated with surgical site infections (SSIs) and, via its unique mechanism of action, possesses a low… More

Biomimetics for treating biofilm-embedded infections

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency / Branch: DOD / ARMY
Research Institution: University of Massachusetts Amherst
Principal Investigator: Richard W. Scott, VP Research – (484) 598-2336
Award Amount: $749,860.00
RI Contact: Carol Sprague
Abstract:
Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop new antibiotics that operate through novel mechanisms which overcome the biofilm environment.… More

Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard W. Scott – 484-598-2336
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is a global disease causing gt 500 million clinical cases and gt 1 million deaths each year. Moreover, drug resistant Plasmodium falciparum has become a major problem. Therefore, it is crucial to discover new classes of drugs for anti-malarial drug… More

A Topical Host Defense Peptide Mimetic for Oral Mucositis

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard W. Scott – 484-598-2336
Award Amount: $161,376.00
Abstract:
DESCRIPTION (provided by applicant): Oral ulcerative mucositis is a common, painful, dose-limiting toxicity of chemotherapy and radiation therapy for cancer, and represents an important unmet clinical need with 450,000 Americans suffering from mucositis each year. It impacts virtually all patients… More